BIOMAT Database Logo BIOMAT Database Logo

Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. 2001

M M Berrey, and T Schacker, and A C Collier, and T Shea, and S J Brodie, and D Mayers, and R Coombs, and J Krieger, and T W Chun, and A Fauci, and S G Self, and L Corey
Department of Medicine, University of Washington, Seattle, WA, USA.

Immunologic data supporting immediate antiretroviral therapy in primary human immunodeficiency virus type 1 (HIV-1) infection are emerging; however, clinical benefit has not been demonstrated. The clinical and virologic course of 47 patients who were enrolled from September 1993 through June 1996 and who were not initially treated with potent therapy was compared with the course of 20 patients who immediately began therapy with zidovudine, lamivudine, and indinavir. Demographic and baseline laboratory data were comparable. During 78 weeks of follow-up, the early-treatment cohort showed a reduced frequency of opportunistic infections (5% vs. 21.3%; relative risk, 0.11; P=.02), less frequent progression to AIDS (13% vs. 0%), and significantly less frequent nonopportunistic mucocutaneous disorders and respiratory infections (P<.01). Plasma HIV-1 RNA levels were <50 copies/mL in all patients who continued therapy; however, after 9--12 months, HIV-1 remained detectable in latently infected CD4(+) T cells and in lymph node mononuclear cells. Combination antiretroviral therapy during primary HIV-1 infection demonstrated a decreased frequency of minor opportunistic infections, mucocutaneous disorders, and respiratory infections and reduced progression to AIDS.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008214 Lymphocytes White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS. Lymphoid Cells,Cell, Lymphoid,Cells, Lymphoid,Lymphocyte,Lymphoid Cell
D008297 Male Males
D010349 Patient Compliance Voluntary cooperation of the patient in following a prescribed regimen. Client Adherence,Client Compliance,Non-Adherent Patient,Patient Adherence,Patient Cooperation,Patient Noncompliance,Patient Non-Adherence,Patient Non-Compliance,Patient Nonadherence,Therapeutic Compliance,Treatment Compliance,Adherence, Client,Adherence, Patient,Client Compliances,Compliance, Client,Compliance, Patient,Compliance, Therapeutic,Compliance, Treatment,Cooperation, Patient,Non Adherent Patient,Non-Adherence, Patient,Non-Adherent Patients,Non-Compliance, Patient,Nonadherence, Patient,Noncompliance, Patient,Patient Non Adherence,Patient Non Compliance,Patient, Non-Adherent,Therapeutic Compliances,Treatment Compliances
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

M M Berrey, and T Schacker, and A C Collier, and T Shea, and S J Brodie, and D Mayers, and R Coombs, and J Krieger, and T W Chun, and A Fauci, and S G Self, and L Corey
Questions about results reported with potent antiretroviral therapy for human immunodeficiency virus type 1 infection.
April 2000, The Journal of infectious diseases,
M M Berrey, and T Schacker, and A C Collier, and T Shea, and S J Brodie, and D Mayers, and R Coombs, and J Krieger, and T W Chun, and A Fauci, and S G Self, and L Corey
Antiretroviral therapy of human immunodeficiency virus type-1 (HIV-1) infection.
August 1995, Australian and New Zealand journal of medicine,
M M Berrey, and T Schacker, and A C Collier, and T Shea, and S J Brodie, and D Mayers, and R Coombs, and J Krieger, and T W Chun, and A Fauci, and S G Self, and L Corey
Combination antiretroviral therapy for the treatment of human immunodeficiency virus type-1 infection.
April 1995, Proceedings of the Association of American Physicians,
M M Berrey, and T Schacker, and A C Collier, and T Shea, and S J Brodie, and D Mayers, and R Coombs, and J Krieger, and T W Chun, and A Fauci, and S G Self, and L Corey
Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy.
April 1998, The Journal of infectious diseases,
M M Berrey, and T Schacker, and A C Collier, and T Shea, and S J Brodie, and D Mayers, and R Coombs, and J Krieger, and T W Chun, and A Fauci, and S G Self, and L Corey
Rapid progression to human immunodeficiency virus type 1 disease.
June 1996, The Journal of infectious diseases,
M M Berrey, and T Schacker, and A C Collier, and T Shea, and S J Brodie, and D Mayers, and R Coombs, and J Krieger, and T W Chun, and A Fauci, and S G Self, and L Corey
Highly active antiretroviral therapy for the treatment of Kaposi's sarcoma associated with primary human immunodeficiency virus type-1 infection.
August 2000, Japanese journal of infectious diseases,
M M Berrey, and T Schacker, and A C Collier, and T Shea, and S J Brodie, and D Mayers, and R Coombs, and J Krieger, and T W Chun, and A Fauci, and S G Self, and L Corey
Serum factors in the progression of human immunodeficiency virus type 1 infection to AIDS.
January 1990, Journal of clinical laboratory analysis,
M M Berrey, and T Schacker, and A C Collier, and T Shea, and S J Brodie, and D Mayers, and R Coombs, and J Krieger, and T W Chun, and A Fauci, and S G Self, and L Corey
Nonreactive Human Immunodeficiency Virus Type 1 Rapid Tests After Sustained Viral Suppression Following Antiretroviral Therapy Initiation During Primary Infection.
May 2018, The Journal of infectious diseases,
M M Berrey, and T Schacker, and A C Collier, and T Shea, and S J Brodie, and D Mayers, and R Coombs, and J Krieger, and T W Chun, and A Fauci, and S G Self, and L Corey
Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS.
November 2002, Journal of virology,
M M Berrey, and T Schacker, and A C Collier, and T Shea, and S J Brodie, and D Mayers, and R Coombs, and J Krieger, and T W Chun, and A Fauci, and S G Self, and L Corey
Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection.
March 1995, The Journal of infectious diseases,
Copied contents to your clipboard!